• OPEN AN ACCOUNT
Indian Indices
Nifty
25,082.30 -67.55
(-0.27%)
Sensex
82,253.46 -247.01
( -0.30%)
Bank Nifty
56,765.35 10.65
( 0.02%)
Nifty IT
37,273.70 -419.55
( -1.11%)
Global Indices
Nasdaq
44,384.39 -287.26
(-0.64%)
Dow Jones
6,279.98 -21.48
(-0.34%)
Hang Seng
39,468.95 -100.73
(-0.25%)
Nikkei 225
8,941.12 -34.54
(-0.38%)
Forex
USD-INR
85.68 -0.05
(-0.06%)
EUR-INR
100.36 -0.05
(-0.05%)
GBP-INR
116.41 -0.07
(-0.06%)
JPY-INR
0.59 0.00
(0.19%)

EQUITY - MARKET SCREENER

Nath Bio-Genes (India) Ltd
Industry :  Miscellaneous
BSE Code
ISIN Demat
Book Value()
537291
INE448G01010
341.3302463
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
NATHBIOGEN
10.31
428.92
EPS(TTM)
Face Value()
Div & Yield %
21.89
10
0.89
 

Transformers and Rectifiers ends higher after bagging export order worth $16.65 million
Jun 20,2025

The contract is for supplying 12 units of various types of transformers.

The transformers have to be delivered by next financial year.

Gujarat-based Transformers & Rectifiers (India) is engaged in manufacturing of transformers and reactors in India. It erves a wide range of sectors, including power generation, transmission and distribution, railways, renewable energy, infrastructure, industrial manufacturing, etc.

The company's consolidated net profit surged 125% to Rs 94.17 crore on a 32% increase in revenue from operations to Rs 676.48 crore in Q4 March 2025 over Q4 March 2024.